Jan Wehkamp

Company: Janssen

Job title: Vice President & GI DAS Lead

Seminars:

Defining Patient Populations for the Next Wave of IBD Treatments – The Janssen Approach 4:00 pm

Where are we going and where are we today? From all comer populations to targeting differentiated patient populations – which role do molecular markers play and in which programs could they be critical? Combination therapy development in IBD is behind other areas in medicine (e.g. HIV, hepatitis, oncology) – could molecular phenotyping help to advance…Read more

day: Day One